Abstract

The present provides a condensed pyridine compound (I) represented by the following formula:

(wherein, R² represents

$$\left(\begin{array}{c} + N \\ \end{array} \right) \left(\begin{array}{c} +$$

ring A represents benzene ring, pyridine ring, thiophene ring or furan ring; and

B represents

$$\left(O)z \xrightarrow{\mathbb{R}^7} \mathbb{R}^8 \right) \xrightarrow{Q - (CH_2)m} \mathbb{R}^{10}$$

$$\begin{pmatrix}
O \\
(C H_2)p
\end{pmatrix}$$

$$\begin{pmatrix}
P^{13} \\
O
\end{pmatrix}$$

$$\begin{pmatrix}
P^{14} \\
O
\end{pmatrix}$$

$$\begin{array}{c}
\begin{array}{c}
\begin{array}{c}
CH_2 \\
\end{array}
\end{array}$$



$$R^{17}$$

$$R^{18}$$

$$R^{20}$$

$$R^{21}$$

$$R^{22}$$

$$R^{22}$$

$$R^{23}$$

$$R^{25}$$

$$R^{26}$$

$$R^{27}$$

$$R^{29}$$

$$R^{29}$$

$$R^{30}$$

$$R^{30}$$

its pharmaceutically acceptable salt or hydrates thereof, which is a clinically useful medicament having a serotonin antagonism, in particular, that for treating, ameliorating or preventing spastic paralysis or central muscle relaxants for ameliorating myotonia.

m *3